# A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.

> **NCT02635945** · PHASE2 · COMPLETED · sponsor: **Palobiofarma SL** · enrollment: 8 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** PBF-680
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02635945
- **Lead sponsor:** Palobiofarma SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-11-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-06-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635945, "A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02635945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*